XTX Topco Ltd Buys New Shares in Charles River Laboratories International, Inc. (NYSE:CRL)

XTX Topco Ltd bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 2,921 shares of the medical research company's stock, valued at approximately $539,000.

Other large investors have also modified their holdings of the company. Broyhill Asset Management bought a new position in shares of Charles River Laboratories International in the 4th quarter worth about $2,388,000. Qtron Investments LLC acquired a new position in Charles River Laboratories International in the fourth quarter valued at approximately $542,000. Sterling Capital Management LLC grew its stake in shares of Charles River Laboratories International by 53.8% in the fourth quarter. Sterling Capital Management LLC now owns 3,086 shares of the medical research company's stock worth $570,000 after purchasing an additional 1,080 shares in the last quarter. Covestor Ltd increased its stake in Charles River Laboratories International by 33.9% during the 4th quarter. Covestor Ltd now owns 438 shares of the medical research company's stock valued at $81,000 after buying an additional 111 shares during the period. Finally, Capital Fund Management S.A. raised its position in shares of Charles River Laboratories International by 13.8% during the 4th quarter. Capital Fund Management S.A. now owns 27,786 shares of the medical research company's stock worth $5,129,000 after buying an additional 3,371 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of the business's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO James C. Foster bought 6,075 shares of the business's stock in a transaction on Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the purchase, the chief executive officer now directly owns 183,639 shares in the company, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. The Goldman Sachs Group downgraded Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their target price for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price on the stock in a report on Monday, March 3rd. Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price objective for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. Robert W. Baird decreased their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a research note on Thursday, February 20th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research note on Thursday, February 20th. One analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $182.00.

Charles River Laboratories International Stock Performance

Shares of CRL traded down $1.25 during trading hours on Friday, reaching $114.52. 355,201 shares of the company traded hands, compared to its average volume of 914,533. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock's fifty day moving average is $147.53 and its 200 day moving average is $171.73. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15. The stock has a market cap of $5.62 billion, a P/E ratio of 763.44, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company's quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter last year, the company earned $2.46 EPS. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).